AA
CABA icon

AlphaCentric Advisors’s Cabaletta Bio CABA Stock Holding History

AlphaCentric Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-70,000
Closed -$524K – 233
2024
Q2 		$524K Buy
70,000
+5,000
+8% +$61.3K 0.39% 76
2024
Q1 		$1.11M Buy
+65,000
New +$1.4M 0.67% 60

Other funds holding CABA

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

AlphaCentric Advisors's CABA Position: Q3 2024 in Review

AlphaCentric Advisors sold out of Cabaletta Bio (CABA) in Q3 2024, closing a stake of 70,000 shares — an estimated $524K sold.

AlphaCentric Advisors first reported a position in CABA in Q1 2024 and held it in 2 quarters. The position peaked at $1.11M in Q1 2024. 120 funds tracked by Wall St. Rank hold CABA as of Q3 2024.

  • AlphaCentric Advisors reported no remaining Cabaletta Bio position as of Q3 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 70,000 Cabaletta Bio shares in Q3 2024, an estimated $524K.
  • AlphaCentric Advisors first reported a position in Cabaletta Bio in Q1 2024 and held it in 2 quarters.
  • AlphaCentric Advisors's Cabaletta Bio position peaked at $1.11M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2024.

Based on AlphaCentric Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.